skip to Main Content

CA19-9 and Apolipoprotein-A2 isoforms as Detection Markers for Pancreatic Cancer: A Prospective Evaluation

Newsfeed image, light gray text on dark gray background
Considering their recent identification of unique processing patterns of apolipoprotein A2 (ApoA2) in patients with pancreatic cancer, researchers undertook this work prospectively evaluating an ApoA2 isoform (“ApoA2-ATQ/AT”), alone and in combination with carbohydrate antigen 19–9 (CA19-9), as an early detection biomarker for pancreatic cancer, for the first time.

In 156 patients with pancreatic cancer and 217 matched controls within the European EPIC cohort, ELISA measurements of CA19-9 and ApoA2-ATQ/AT were performed using plasma samples collected up to 60 months prior to diagnosis. Read more . . . 

Back To Top